Abbott ACT I debut
This article was originally published in The Gray Sheet
Executive Summary
First patient is enrolled in firm's 50-site, 1,500 patient Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease Trial (ACT I), Abbott announces March 31. The randomized clinical trial will compare carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients in support of a PMA for Mednova's self-expanding nitinol Xact carotid stent and Emboshield embolic protection device (1"The Gray Sheet" Jan. 24, 2005, p. 3)...
You may also be interested in...
Asymptomatic Carotid Stenting Evaluated By Abbott’s ACT-I Study
Abbott's ACT-I trial is the first randomized clinical trial comparing carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.